NVS Novartis AG Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
17:23
Jul 18
Jul 18
US pharma reshoring benefits Lilly and Novartis.
Efforts to restore critical pharmaceutical production in America are a bright spot, with major companies like Eli Lilly and Novartis already committing to reshoring and pouring concrete on new facilities in the U.S., supported by policy pushes and commitments from 17 pharma firms.
LOW
03:46
Jul 07
Jul 07
Novartis acquires London-based biotech firm for 1.5 billion dollars driven by impending patent expirations on key drugs.
01:57
Jul 07
Jul 07
Novartis announced an acquisition of Myricx Bio for up to $1.5 billion, a factual M&A report without the author expressing a personal position.
LOW
04:56
Apr 03
Apr 03
BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.
12:57
Mar 27
Mar 27
Novartis agreed to acquire biotech firm Excelergy for up to $2 billion to strengthen its immunology and cancer drug portfolios. Acquisition enhances Novartis's growth prospects and diversifies its product pipeline, which is positive for future earnings and market position. LONG due to strategic expansion and positive market reaction, with shares outperforming peers year-to-date. Integration challenges or pipeline failures could undermine expected benefits.
00:50
Feb 28
Feb 28
Cramer notes that February "demolished software" and "minimized hardware" but the winners were "prosaic companies with popular brands" and "earthmovers." In a month of indecision, inflation, and rate fears, capital is fleeing high-beta tech and hiding in tangible, defensive value stocks and industrials. LONG. These are the current safe havens in a volatile market. A sudden return to "risk-on" sentiment could see these lag behind tech.
00:50
Feb 28
Feb 28
February winners were "prosaic companies" with popular brands and earth movers. In a month where software and hardware were demolished, capital hid in these defensive names. This trend is the current market regime. Winners/Holds. Rotation back into risk-on tech.
About NVS Analyst Coverage
Buzzberg tracks NVS (Novartis AG) across 5 sources. 5 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (71%). 7 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Jamieson Greer, FirstSquawk, BarbarianCap.